1999
DOI: 10.1056/nejm199901073400115
|View full text |Cite
|
Sign up to set email alerts
|

Fatal Hematoma during Treatment with Adjusted-Dose Subcutaneous Heparin Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
4
0
2

Year Published

2000
2000
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(6 citation statements)
references
References 2 publications
0
4
0
2
Order By: Relevance
“…[16] RSH can be a relatively benign or life-threatening clinical condition depending on the size and location of the bleeding, the general health and the hemodynamic status of the patient. [17][18][19] It can also be confused with an intraabdominal inflammatory process that may lead to delayed diagnosis or unnecessary laparotomy before appropriate treatments begin. [20,21] RSH is frequently seen during the fifth and sixth decades.…”
Section: Discussionmentioning
confidence: 99%
“…[16] RSH can be a relatively benign or life-threatening clinical condition depending on the size and location of the bleeding, the general health and the hemodynamic status of the patient. [17][18][19] It can also be confused with an intraabdominal inflammatory process that may lead to delayed diagnosis or unnecessary laparotomy before appropriate treatments begin. [20,21] RSH is frequently seen during the fifth and sixth decades.…”
Section: Discussionmentioning
confidence: 99%
“…[34] Anticoagulation therapy has also been implicated as a risk factor for RSH. [56] It is unknown if coagulopathies caused by liver disease increase bleeding in RSH.…”
Section: Discussionmentioning
confidence: 99%
“…Fatality from RSH is uncommon, but has been reported in the literature. [589] The overall reported mortality rate in both surgical and conservatively managed patients is estimated to be 4% with increased mortality in patients on anticoagulation and those requiring surgical intervention. [8]…”
Section: Discussionmentioning
confidence: 99%
“…Retroperitoneale Hämatome können als Komplikation unter antikoagulativer Therapie auftreten. Während die Inzidenz von hämorrhagischen Komplikationen unter antikoagulativer Therapie zwischen 0,25 bis 23 % beträgt [15,32], wird die Inzidenz von retroperitonealen Hämatomen unter antikoagulativer Therapie mit 6,6 % bei Patienten unter Heparintherapie wegen venöser Thrombose angegeben [33]. Eine Durchsicht der Literatur zeigt, dass bislang nur wenig über das Management von retroperitonealen Hämatomen publiziert wurde.…”
Section: Diskussionunclassified